相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials
Boni Elewski et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Biologics and small molecules in patients with scalp psoriasis: a systematic review
Adel Alsenaid et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Abby S. Van Voorhees et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)
A. S. Paller et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Efficacy and safety of adalimumab in difficult-to-treat psoriasis
Caterina Lanna et al.
DERMATOLOGIC THERAPY (2020)
Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
M. A. Menter et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Efficacy and safety of risankizumab in psoriasis patients who failedanti-IL-17, anti-12/23 and/or antiIL-23: Preliminary data of a real-life 16-week retrospective study
Matteo Megna et al.
DERMATOLOGIC THERAPY (2020)
Apremilast for psoriasis treatment
Jose-Manuel Carrascosa et al.
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA (2020)
Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs
M. Megna et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study
Natalia Rompoti et al.
DERMATOLOGIC THERAPY (2019)
Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis
Anna Campanati et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
Andreas Pinter et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2019)
Psoriatic disease treatment nowadays: unmet needs among the jungle of biologic drugs and small molecules
Matteo Megna et al.
CLINICAL RHEUMATOLOGY (2018)
Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails
Joseph F. Merola et al.
DERMATOLOGIC THERAPY (2018)
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
Craig Leonardi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis
E. Papadavid et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials
Peter Foley et al.
JAMA DERMATOLOGY (2018)
Scalp psoriasis: report of efficient treatment with secukinumab
Giuseppe Pistone et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Managing Scalp Psoriasis: An Evidence-Based Review
Ting-Shun Wang et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Kristian Reich et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
Hidehisa Saeki et al.
JOURNAL OF DERMATOLOGY (2017)
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis
P. Gisondi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Apremilast for the management of moderate to severe plaque psoriasis
Ramya Vangipuram et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
Gillian M. Keating
DRUGS (2017)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2016)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
Phoebe Rich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre
C. Fotiadou et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
R. G. Langley et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study
D. Thaci et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Craig Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Newer trends in the management of psoriasis at difficult to treat locations: Scalp, palmoplantar disease and nails
Sanjeev Handa
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2010)
分享论文
